Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674100 | 0.85 | ADORA2A (0.37) | ADORA2AADORA1CCNCCDK8PIM3 | |
| SCHEMBL20674103 | 0.83 | PAK1 (0.35) | — | |
| SCHEMBL23937708 | 0.75 | PTPN11 (0.32) | — | |
| SCHEMBL20674098 | 0.73 | MAP2K2 (0.36) | PIM1LMNAPKMALDH1A1SYK | |
| SCHEMBL20674481 | 0.70 | PTPN11 (0.33) | — | |
| SCHEMBL21959641 | 0.70 | MAP2K2 (0.36) | LMNAPKMALDH1A1SYKMAP2K2 | |
| SCHEMBL20674102 | 0.68 | BAZ2B (0.36) | SYK | |
| SCHEMBL20674525 | 0.63 | CA1 (0.39) | LMNAPOLB | |
| SCHEMBL20674106 | 0.62 | BRD4 (0.39) | PKMMAP2K2MAP2K1 | |
| SCHEMBL21958617 | 0.62 | PTPN11 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | ADORA2A 4789/4885ADORA1 4452/4885CCNC 617/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | ADORA2A 4797/4885ADORA1 4503/4885CCNC 467/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | ADORA2A 4789/4885ADORA1 4452/4885CCNC 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.